Emergent Biosolutions Inc. took another step in its quest to expand its pipeline and ramp up commercial revenues by sealing a deal to acquire Canada’s Cangene Corp. for $222 million, or $3.24 per share on a fully diluted basis. The boards of directors of both companies approved the transaction, which gives Emergent three specialty products included in the U.S. Strategic National Stockpile and four commercial specialty therapies.
Astellas Pharma U.S. Inc., a subsidiary of Astellas Pharma Inc., of Tokyo, said the Centers for Medicare & Medicaid Services assigned a unique Healthcare Common Procedure Coding System code for Astagraf XL (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients receiving a kidney transplant used with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction.
Mallinckrodt Inc., of St. Louis, said the Phase III trial of MNK-155, an extended-release oral formulation of hydrocodone and acetaminophen, met the primary efficacy endpoint of change in pain from baseline over 48 hours compared to placebo in managing moderate to moderately severe acute pain where the use of an opioid analgesic is appropriate.
Celator Pharmaceuticals Inc., of Ewing, N.J., said independent data and safety monitoring board for the company’s Phase III study comparing CPX-351 (cytarabine/daunorubicin) liposome injection to the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3 ) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia should continue as planned without any modifications.
Ico Therapeutics Inc., of Vancouver, British Columbia, said its oral amphotericin B is moving into in vitro testing with study partners in Montreal to examine the role of the formulation in targeting latent HIV reservoirs.
Synta Pharmaceuticals Corp., of Lexington, Mass., presented results from the single-arm, multicenter Phase II proof-of-concept ENCHANT-1 trial evaluating the efficacy and safety of lead candidate ganetespib as monotherapy to treat HER2+ (Cohort A) or triple-negative, or TNBC (Cohort B), patients previously untreated for locally advanced or metastatic disease.
Mimedx Group Inc., of Marietta, Ga., said it priced an underwritten public offering of 5 million shares of its common stock at $6.80 per share for gross proceeds of $34 million.
Oversized hopes for what the company designed as an exploratory Phase II trial led to Immunocellular Therapeutics Ltd.’s stock plunge, after the company disclosed mixed results with its dendritic cell-based vaccine in glioblastoma multiforme (GBM), said CEO Andrew Gengos.
RSS